Thirty percent of M&A deals involving patented technology get repriced or killed during due diligence. Not because the technology fails — because the patents fail. Hayat Amin has run patent due diligence on both sides of the table — structuring portfolios pre-sale and tearing them apart as the buyer's advisor. The pattern repeats: founders overvalue what they filed and ignore what they forgot to file. Acquirers punish both equally.
Patent due diligence in M&A is the single workstream most likely to change the deal price after the LOI is signed. Miss a broken chain of title, an undisclosed cross-licence, or an active IPR proceeding, and the repricing conversation starts within 48 hours. Here is the 14-point checklist that separates clean closes from collapsed deals.
What Is Patent Due Diligence in M&A?
Patent due diligence in M&A is the structured audit an acquirer runs to verify that a target's patent portfolio is valid, enforceable, properly owned, and commercially aligned with the deal thesis. It runs parallel to financial due diligence but requires specialised IP expertise most corporate M&A teams lack. At Beyond Elevation, patent due diligence starts 60 to 90 days before the LOI — not after.
The scope covers four categories: ownership (who actually holds title), validity (can the patents survive challenge), scope (do the claims protect what the acquirer is paying for), and risk (undisclosed encumbrances, third-party infringement, litigation exposure). Skip any category and the deal flies blind.
The 14-Point Patent Due Diligence Checklist Acquirers Run
Acquirers who close patent-intensive deals without repricing use a structured checklist covering ownership, validity, scope, and risk — four categories mapping every angle of patent exposure. Hayat Amin developed the Beyond Elevation Patent Due Diligence Framework after watching the same four gaps sink deals across three continents. Here are the 14 items that separate a clean close from a repriced mess.
Ownership (Items 1–4)
1. Chain of title. Confirm every patent is assigned to the selling entity — not a founder's name, a dormant subsidiary, or a departed co-inventor. Missing assignments are the most common defect. One unsigned inventor declaration clouds title on an entire patent family.
2. Inventor verification. Verify all named inventors are correct and complete. Incorrect inventorship is a basis for invalidity in most jurisdictions. A former contractor omitted from the inventor list creates a post-close invalidation vector.
3. IP assignment agreements. Pull every employment contract and contractor SOW. Confirm each contains an unambiguous IP assignment clause. Gaps surface months after closing when a former engineer claims ownership rights.
4. Government and university rights. If any patent arose from government-funded research (Bayh-Dole) or university collaboration, verify march-in rights, retained licences, and revenue-sharing obligations. These encumbrances transfer with the patent and constrain the acquirer's freedom to enforce.
Validity (Items 5–8)
5. Prosecution history. Read the file wrapper for each key patent. Narrow claim amendments during prosecution limit protection and signal how much the patentee conceded. A patent granted after six rounds of amendment is a weaker asset than one allowed on first response.
6. Prior art scan. Run a targeted search against the broadest claims. An obvious reference missed during prosecution means the patent is vulnerable to post-grant challenge — IPR in the US, opposition at the EPO. Acquirers who skip this are buying litigation risk.
7. Maintenance fee status. Verify all renewal fees are current in every jurisdiction. A single missed payment in a key market means the patent has lapsed. Most jurisdictions make reinstatement expensive or impossible.
8. Post-grant challenge history. Check whether any patent has faced IPR, opposition, or reexamination. A patent that survived challenge is stronger. One that lost claims is weaker than its face value suggests.
Scope (Items 9–11)
9. Claim-to-product mapping. Map the claims of each key patent to the target's actual products and revenue streams. Hayat Amin calls this the "claim-revenue alignment test" — if the highest-revenue product line sits outside the broadest claims, the portfolio is decorative, not defensive.
10. Geographic coverage. Check filing jurisdictions against the acquirer's target markets. A US-only portfolio is insufficient for a company selling globally. Missing filings in the EU, China, Japan, or Korea are gaps competitors exploit without consequence.
11. Remaining patent life. Calculate remaining term including terminal disclaimers and patent term adjustments. A portfolio averaging three years of remaining life is worth materially less than one with twelve years of protection. Short-dated portfolios need a pipeline of continuations to sustain value.
Risk (Items 12–14)
12. Licence and encumbrance review. Pull every licence, cross-licence, covenant not to sue, and standards commitment. Existing licences transfer with the patent. One overlooked cross-licence to a major competitor guts the portfolio's exclusionary value overnight.
13. Third-party infringement exposure. Assess whether the target's products infringe third-party patents. Acquirers inherit liability. A freedom-to-operate analysis on core products is not optional — it is insurance against post-close injunction risk.
14. Litigation history. Review all past, pending, and threatened patent litigation — as plaintiff and defendant. Active disputes create indemnification obligations and signal enforcement risk the acquirer must price into the deal.
Which 4 Patent Defects Kill 30% of M&A Deals?
Four specific patent due diligence failures account for the majority of repriced or terminated M&A deals. Beyond Elevation runs these four checks first — before spending weeks on the full 14-point review — because each one alone can collapse a deal.
Broken chain of title. The most common killer. A founder filed patents under a personal name and never assigned them to the company. Or a co-inventor who contributed to one claim never signed an assignment. In one restructuring Hayat Amin reviewed, the target's entire patent family — eleven patents — traced back to a university spin-out agreement that reserved an irrevocable licence. The acquirer found this on day 47. The deal repriced by 35%.
Claim scope mismatch. The patents exist, but the claims do not cover the product the acquirer wants. Founders file broad provisionals, narrow during prosecution, and never update the story. The acquirer pays for a $40 million product line. The claims actually cover a feature deprecated two years ago.
Undisclosed encumbrances. Cross-licences, standards commitments, and settlement agreements that limit the acquirer's enforcement rights. Sellers omit these from the disclosure schedule — usually from ignorance, not malice. The CTO who signed a cross-licence five years ago forgot to tell legal. The acquirer discovers it in week six and the enforcement strategy collapses.
Active IPR proceedings. A patent under inter partes review is a liability with a probability-weighted outcome, not an asset. If the USPTO cancels even a subset of claims, the portfolio valuation shifts materially. Sellers who disclose pending IPR late signal disorganisation or concealment. Both kill trust and kill deals.
When Should Patent Due Diligence Start in an M&A Process?
Patent due diligence in M&A should begin before the letter of intent, not after. Sellers who run a pre-sale patent audit surface and fix defects on their own timeline. Buyers who wait until the LOI is signed negotiate with a ticking clock and limited leverage. Hayat Amin's standard recommendation: 90 days pre-LOI for sellers, 30 days pre-LOI for buyers.
For sellers, the pre-sale audit follows the same 14-point framework. The difference is motive — fix problems, not discover them. Missing assignments get recorded. Lapsed fees get reinstated. Claim-revenue gaps get addressed with continuation filings. Every defect fixed pre-sale translates directly to deal price preserved at close.
For buyers, early engagement means commissioning a patent landscape analysis before entering formal diligence. This preliminary scan — ownership records, prosecution status, litigation history — takes two weeks and costs a fraction of the repricing risk it eliminates. Companies with patents are 10.2x more likely to secure early-stage funding and command higher exit multiples, but only when the portfolio survives diligence.
How Does Beyond Elevation Structure Patent Due Diligence in M&A Differently?
Most M&A firms outsource patent diligence to patent attorneys who bill hourly and deliver a static report. Beyond Elevation embeds a patent strategist inside the deal team from pre-LOI through close. A patent attorney tells you what the claims say. A strategist tells you what the claims are worth to the buyer's business model.
This operator-first approach surfaces commercial gaps legal diligence misses. A patent may be valid and properly assigned but commercially irrelevant to the acquirer's roadmap. That distinction — legal soundness versus commercial value — is where Hayat Amin's IP Defensibility 7-Point Test intersects with M&A diligence. The 14-point checklist confirms the portfolio is clean. The defensibility test confirms it is worth paying for.
FAQ
How long does patent due diligence take in M&A?
Patent due diligence in M&A takes 30 to 60 days for portfolios under 50 patents. Multi-jurisdictional filings extend the timeline to 60 to 90 days. Starting before the LOI prevents the diligence clock from compressing the analysis into a window that misses critical defects.
What is the difference between patent due diligence and IP due diligence?
Patent due diligence focuses on patents and patent applications — ownership, validity, scope, and risk. IP due diligence covers all intellectual property including trademarks, copyrights, trade secrets, and data assets. Patent diligence is a specialised subset requiring prosecution and claim-analysis expertise most generalist IP lawyers lack.
Who should run patent due diligence in an M&A deal?
The team needs patent prosecution knowledge, litigation risk assessment, and commercial valuation expertise. A patent attorney handles the legal review. A patent strategist — like the advisory team at Beyond Elevation — handles the commercial alignment that determines what the portfolio is actually worth to the buyer.
Can patent issues kill an M&A deal?
Yes. Broken chain of title, undisclosed encumbrances, and active IPR proceedings are the three most common deal killers. Roughly 30% of patent-intensive M&A deals get repriced or terminated due to defects found during patent due diligence in M&A. Pre-sale audits eliminate most of these before they reach the negotiating table.